Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6254)
All Articles published online
|
Publishing Process of This Article
|
Dec 15, 2013 (publication date) through Nov 21, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Diabetes
ISSN
1948-9358
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Kei A, Liberopoulos E, Elisaf M. Effect of hypolipidemic treatment on glycemic profile in patients with mixed dyslipidemia. World J Diabetes 2013; 4(6): 365-371 [PMID: 24379928 DOI: 10.4239/wjd.v4.i6.365] |
|---|---|
| URL: | https://www.wjgnet.com/1948-9358/full/v4/i6/365.htm |
| Number | Citing Articles |
| 1 |
Zhi-bin Wang, Su Zhang, Ya Li, Rong-mei Wang, Ling-chang Tong, Yue Wang, Wei-ye Liu, Ding-feng Su, Ye Tu, Li-chao Zhang, Ling Li. LY333531, a PKCβ inhibitor, attenuates glomerular endothelial cell apoptosis in the early stage of mouse diabetic nephropathy via down-regulating swiprosin-1. Acta Pharmacologica Sinica 2017; 38(7): 1009 doi: 10.1038/aps.2016.172
|
| 2 |
Hossein Nikroo, Seyyed Reza Attarzadeh Hosseini, Mehrdad Fathi, Mohammad Ali Sardar, Majid Khazaei. The effect of aerobic, resistance, and combined training on PPAR-α, SIRT1 gene expression, and insulin resistance in high-fat diet-induced NAFLD male rats. Physiology & Behavior 2020; 227: 113149 doi: 10.1016/j.physbeh.2020.113149
|
| 3 |
Michael S. Kostapanos, Christos V. Rizos, Moses S. Elisaf. Benefit–Risk Assessment of Rosuvastatin in the Treatment of Atherosclerosis and Related Diseases. Drug Safety 2014; 37(7): 481 doi: 10.1007/s40264-014-0169-4
|
| 4 |
T. D. Filippatos, M. S. Elisaf. Pitavastatin and carbohydrate metabolism: what is the evidence?. Expert Review of Clinical Pharmacology 2016; 9(7): 955 doi: 10.1586/17512433.2016.1165607
|
| 5 |
Theodosios D Filippatos, Moses S Elisaf. Safety considerations with fenofibrate/simvastatin combination. Expert Opinion on Drug Safety 2015; 14(9): 1481 doi: 10.1517/14740338.2015.1056778
|
| 6 |
Anastazia Kei, Constantinos Tellis, Evangelos Liberopoulos, Alexandros Tselepis, Moses Elisaf. Effect of Switch to the Highest Dose of Rosuvastatin Versus Add‐on‐Statin Fenofibrate Versus Add‐on‐Statin Nicotinic Acid/Laropiprant on Oxidative Stress Markers in Patients with Mixed Dyslipidemia. Cardiovascular Therapeutics 2014; 32(4): 139 doi: 10.1111/1755-5922.12072
|
| 7 |
Konstantinos Kargiotis, Vasilios G Athyros, Olga Giouleme, Niki Katsiki, Evangelia Katsiki, Panagiotis Anagnostis, Chrysoula Boutari, Michael Doumas, Asterios Karagiannis, Dimitri P Mikhailidis. Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome. World Journal of Gastroenterology 2015; 21(25): 7860-7868 doi: 10.3748/wjg.v21.i25.7860
|
| 8 |
Sebhat Erqou, C. Christine Lee, Amanda I. Adler. Statins and glycaemic control in individuals with diabetes: a systematic review and meta-analysis. Diabetologia 2014; 57(12): 2444 doi: 10.1007/s00125-014-3374-x
|
| 9 |
Anastazia Kei, Evangelos C. Rizos, Moses Elisaf. Statin use in prediabetic patients: rationale and results to date. Therapeutic Advances in Chronic Disease 2015; 6(5): 246 doi: 10.1177/2040622315596118
|
| 10 |
Vivencio Barrios, Carlos Escobar, Arrigo Francesco Giuseppe Cicero, David Burke, Peter Fasching, Maciej Banach, Eric Bruckert. A nutraceutical approach (Armolipid Plus) to reduce total and LDL cholesterol in individuals with mild to moderate dyslipidemia: Review of the clinical evidence. Atherosclerosis Supplements 2017; 24: 1 doi: 10.1016/j.atherosclerosissup.2016.10.003
|